• Parthasarathy S, Fehr AR. PARP14: A key ADP-ribosylating protein in host-virus interactions? PLoS Pathog. 2022 Jun 9;18(6):e1010535. doi: 10.1371/journal.ppat.1010535. PMID: 35679255; PMCID: PMC9182250.
  • Sherrill LM, Joya EE, Walker A, Roy A, Alhammad YM, Atobatele M, Wazir S, Abbas G, Keane P, Zhuo J, Leung AKL, Johnson DK, Lehtiö L, Fehr AR, Ferraris D. Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain. Bioorg Med Chem. 2022 Aug 1;67:116788. doi: 10.1016/j.bmc.2022.116788. Epub 2022 May 11. PMID: 35597097; PMCID: PMC9093066.
  • Roy A, Alhammad YM, McDonald P, Johnson DK, Zhuo J, Wazir S, Ferraris D, Lehtiö L, Leung AKL, Fehr AR. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening. Antiviral Res. 2022 May 19;203:105344. doi: 10.1016/j.antiviral.2022.105344. Epub ahead of print. PMID: 35598780; PMCID: PMC9119168.
  • Comar CE, Otter CJ, Pfannenstiel J, Doerger E, Renner DM, Tan LH, Perlman S, Cohen NA, Fehr AR, Weiss SR. MERS-CoV endoribonuclease and accessory proteins jointly evade host innate immunity during infection of lung and nasal epithelial cells. Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2123208119. doi: 10.1073/pnas.2123208119. Epub 2022 May 20. PMID: 35594398.
  • Leung AKL, Griffin DE, Bosch J, Fehr AR. The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses. Pathogens. 2022 Jan 14;11(1):94. doi: 10.3390/pathogens11010094. PMID: 35056042; PMCID: PMC8780475.








Complete List of Published Work in MyBibliography: